DigestRedComo funciona
Red
/
Empresas
Av
No verificado

Avenzo Therapeutics, Inc.

Sobre qué escribimos

BiotecnologíaFarmacéuticaMedicina - VariosOncologíaSalud

17 Comunicados de prensa

Ver todos los comunicados de prensa
24/11/2025
Oncología
Higiene alimentaria
Salud
Medicina - Varios
Farmacéutica
Biotecnología
Industria
Avenzo Therapeutics Granted Fast Track Designation for AVZO-103, a Potential Best-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate, for the Treatment of Patients with Urothelial Cancer Previously Treated with Enfortumab Vedotin
Fuente
Avenzo Therapeutics, Inc.
Editor
Business Wire
1.00
0
19/11/2025
Oncología
Material médico sanitario
Salud
Medicina - Varios
Farmacéutica
Biotecnología
Mercado laboral
Avenzo Therapeutics Announces Appointment of Scott Lipman as Chief Financial Officer
Fuente
Avenzo Therapeutics, Inc.
Editor
Business Wire
1.00
0
10/11/2025
Oncología
Salud
Higiene alimentaria
Sanidad
Medicina - Varios
Farmacéutica
Biotecnología
Industria
Avenzo Therapeutics Granted Fast Track Designation for AVZO-1418, a Potential Best-in-Class EGFR/HER3 Bispecific Antibody-Drug Conjugate, for the Treatment of Patients with EGFR-Mutated TKI-Pretreated NSCLC
Fuente
Avenzo Therapeutics, Inc.
Editor
Business Wire
1.00
0
30/10/2025
Eventos
Ciencia
Medicina - Varios
Biotecnología
Salud
Farmacéutica
Sanidad
Oncología
Avenzo Therapeutics to Present Initial Results from the Phase 1 Study of AVZO-021, a Potential Best-in-Class CDK2 Inhibitor, at the 2025 San Antonio Breast Cancer Symposium
Fuente
Avenzo Therapeutics, Inc.
Editor
Business Wire
1.00
0
29/09/2025
Oncología
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Industria
Avenzo Therapeutics Initiates Phase 1/2 Clinical Study of AVZO-103, a Potential Best-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate
Fuente
Avenzo Therapeutics, Inc.
Editor
Business Wire
1.00
0
22/09/2025
Ciencia
Biotecnología
Farmacéutica
Oncología
Salud
Higiene alimentaria
Medicina - Varios
Avenzo Therapeutics Announces $60 Million Series B Financing
Fuente
Avenzo Therapeutics, Inc.
Editor
Business Wire
1.00
0
02/09/2025
Oncología
Salud
Higiene alimentaria
Sanidad
Medicina - Varios
Farmacéutica
Biotecnología
Industria
Avenzo Therapeutics Announces FDA Clearance of Investigational New Drug Application for AVZO-103, a Potential Best-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate
Fuente
Avenzo Therapeutics, Inc.
Editor
Business Wire
1.00
0
08/07/2025
Oncología
Salud
Medicina - Varios
Sanidad
Farmacéutica
Biotecnología
Análisis de Mercados
Industria
Avenzo Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Study of AVZO-1418, a Potential Best-in-Class EGFR/HER3 Bispecific Antibody-Drug Conjugate
Fuente
Avenzo Therapeutics, Inc.
Editor
Business Wire
1.00
0
05/06/2025
Industria
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Oncología
Avenzo Therapeutics Initiates Phase 1/2 Clinical Study of AVZO-023, a Potential Best-in-Class, Novel CDK4 Selective Inhibitor
Fuente
Avenzo Therapeutics, Inc.
Editor
Business Wire
1.00
0
22/05/2025
Industria
Oncología
Higiene alimentaria
Salud
Medicina - Varios
Farmacéutica
Biotecnología
Avenzo Therapeutics Announces FDA Clearance of Investigational New Drug Application for AVZO-1418, a Potential Best-in-Class, Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate
Fuente
Avenzo Therapeutics, Inc.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0